RxDoctor Payments DataLook up a doctor →

Jesse Carr, MD

Neurology · Pasadena, CANPI 1407935125

Payments from drug & device makers

$5,400,119in general payments, 2019–2025

Across 777 payments — averaging $6949.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$2.1M
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$600K
  • AbbVie$474K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$390K
  • Teva Pharmaceuticals USA, Inc.$351K
  • Sage Therapeutics, LLC$300K
  • plus $1.2M from 22 others

What the payments were for

  • Food & beverage$1,52695%
  • Education$745%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,400,119 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$20,754
Medicare patients
44
Services billed
214

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole17$39,842
VraylarCariprazine Hcl15$30,788
Lurasidone Hcl34$27,955
BelsomraSuvorexant11$4,810
Quetiapine Fumarate85$3,544
Clozapine15$2,235
Ziprasidone Hcl12$1,444
Modafinil11$1,239
Bupropion XlBupropion Hcl35$1,082
Olanzapine27$922
Prazosin Hcl11$830
Trazodone Hcl43$825
Desvenlafaxine Succinate ErDesvenlafaxine Succinate17$819
Venlafaxine Hcl ErVenlafaxine Hcl25$645
Clonazepam72$634

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$90$39,84217 claims
AbbVieVraylar$473,789$30,78815 claims
MerckBelsomra$142,614$4,81011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,996 neurology providers in California.

Other neurology in Pasadena

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →